You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence

Abstract

BACKGROUND:

Determining the optimal treatment for biochemical recurrence (BCR) after radical prostatectomy (RP) is challenging.

OBJECTIVE:

We evaluated the ability of CCP score (a prognostic RNA expression signature) to discriminate between systemic disease and local recurrence in patients with BCR after RP.

METHODS:

Sixty patients with BCR after RP were selected for analysis based on: 1) metastatic disease, 2) non-response to salvage external beam radiotherapy (EBRT), and 3) durable response to salvage EBRT. CCP scores were generated from the RNA expression of 46 genes. Logistic regression assessed the association between CCP score and patient group.

RESULTS:

Passing CCP scores were generated for 47 patients with complete clinical and pathologic data. CCP score predicted clinical status when comparing patients with metastatic disease or non-responders to salvage therapy to patients with durable response (p = 0.006). CCP score remained significantly predictive of clinical status after accounting for time to BCR, PSA level at BCR, and Gleason score (p = 0.0031).

CONCLUSIONS:

Elevated CCP score was associated with increased risk of systemic disease, indicating that CCP score may be useful in identifying patients with BCR who are most likely to benefit from salvage radiation therapy.

References

[1] 

Bishoff JT, , Freedland SJ, , Gerber L et al., Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol 192 (2014), 409-414.

[2] 

Cookson MS, , Aus G, , Burnett AL et al., Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177 (2007), 540-545.

[3] 

Cooperberg MR, , Simko JP, , Cowan JE et al., Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort. J Clin Oncol 31 (2013), 1428-1434.

[4] 

Cuzick J, , Berney DM, , Fisher G et al., Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106 (2012), 1095-1099.

[5] 

Cuzick J, , Swanson GP, , Fisher G et al., Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12 (2011), 245-255.

[6] 

Den RB, , Yousefi K, , Trabulsi EJ et al., Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 33 (2015), 944-951.

[7] 

Dotan ZA, , Bianco FJ, , Jr., Rabbani F et al., Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 23 (2005), 1962-1968.

[8] 

Freedland SJ, , Gerber L, , Reid J et al., Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys 86 (2013), 848-853.

[9] 

Han M, , Partin AW, , Pound CR, , Epstein JI, , Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy, The 15-year Johns Hopkins experience. The Urologic Clinics of North America 28 (2001), 555-565.

[10] 

Joniau S, , Briganti A, , Gontero P et al., Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol 67 (2015), 157-164.

[11] 

Kattan MW, , Eastham JA, , Stapleton AM, , Wheeler TM, , Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998), 766-771.

[12] 

Mosley JD, , Keri RA. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics 1 (2008), 11.

[13] 

Pound CR, , Partin AW, , Eisenberger MA, , Chan DW, , Pearson JD, , Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 281 (1999), 1591-1597.

[14] 

Ross AE, , Johnson MH, , Yousefi K et al., Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. Eur Urol 69 (2016), 157-165.

[15] 

Shedden K, , Taylor JMG, , Enkemann SA et al., Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14 (2008), 822-827.

[16] 

Thompson KE, , Hernandez J, , Canby-Hagino ED, , Troyer D, , Thompson IM. Prognostic features in men who died of prostate cancer. J Urol 174 (2005), 553-556.

[17] 

Ward JF, , Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2 (2005), 174-182.

[18] 

Whitfield ML, , Sherlock G, , Saldanha AJ et al., Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13 (2002), 1977-2000.

[19] 

Yossepowitch O, , Eggener SE, , Serio AM et al., Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 53 (2008), 950-959.

[20] 

Zhang J, , Liu B, , Jiang X et al., A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. PloS One 4 (2009), e6274.